Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Inventory (2023 - 2025)

Historic Inventory for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $7.4 million.

  • Zhengye Biotechnology Holding's Inventory changed N/A to $7.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.4 million, marking a year-over-year change of. This contributed to the annual value of $8.1 million for FY2024, which is 178.29% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Inventory stood at $7.4 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Inventory registered a high of $8.1 million during Q4 2024, and its lowest value of $7.4 million during Q2 2025.
  • In the last 3 years, Zhengye Biotechnology Holding's Inventory had a median value of $8.1 million in 2023 and averaged $7.9 million.
  • Data for Zhengye Biotechnology Holding's Inventory shows a peak YoY increase of 9.88% (in 2024) and a maximum YoY decrease of 9.88% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Inventory stood at $8.1 million in 2023, then grew by 0.1% to $8.1 million in 2024, then fell by 8.66% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q2 2025, $8.1 million for Q4 2024, and $8.1 million during Q4 2023.